From Cancer to Neurology: Encouraging Results, Unanswered Questions
A treatment approach already used against certain cancers is being tested for neurological disease. In a small U.S. study of Stiff Person Syndrome (SPS), the rare disorder affecting Céline Dion, researchers observed improvements in a short walking test after a single infusion of an experimental treatment. A neurologist from Rambam Health Care Campus explains what the findings show—and why it is too early to call them a breakthrough.
Stiff Person Syndrome (SPS) , occurs when the immune system mistakenly attacks the nervous system, explains Professor Shahar Shelly, director of the Department of Neurology at Rambam Health Care Campus. The condition causes muscle stiffness and painful spasms that can make walking and other daily activities difficult. Muscle relaxants and medicines that act on the immune system can ease symptoms, though relief may be limited. There is currently no cure.

In a small phase 2 study published in JAMA Neurology, scientists tested an experimental CAR T-cell therapy called mivocabtagene autoleucel. Twenty-six patients ages 32 to 73 received a single infusion of the therapy at three U.S. clinics after earlier treatments that act on the immune system failed to provide enough relief.
Doctors already use CAR T-cell therapy to treat some cancers. For this study, researchers collected T cells from each patient and modified them to recognize and eliminate certain B cells. Both are types of immune cells. The researchers then infused the modified T cells back into each patient. They hope that removing these B cells can interrupt the immune response involved in SPS. Research into SPS is part of a broader effort to see whether CAR T-cell therapies can also help people with autoimmune diseases. Whether this particular approach will work in other neurological conditions remains uncertain.
What changed after four months?
Researchers compared each patient’s results before and after the infusion. Researchers timed how long patients took to walk 25 feet (about 7.6 meters) before treatment and again 16 weeks later. The median reduction in walking time was 45.6%. In absolute terms, the median reduction was 4.8 seconds. Twenty-one of the 26 patients cut their walking time by at least 20%. Eight finished the test in under five seconds, something no patient did before treatment.
Researchers also recorded less muscle stiffness, less sensitivity to stimuli that can trigger spasms, and improvements in measures of disability. The median follow-up was six and a half months. At their last study visit, none of the participants had resumed immunomodulatory therapy for SPS.
“I think we should interpret the data with caution,” says Professor Shelly. He notes that some patients completed the short walking test without a cane or walker. Whether they could also manage without a walking aid in daily life remains an open question. Professor Shelly adds that the assessors knew the patients had received the treatment. That knowledge could have influenced the results, since stress and expectations can affect symptoms.
Professor Shelly also notes that about two-thirds of participants had shown an inadequate response to only one prior immunomodulatory treatment. Only a few participants had received rituximab, an antibody treatment that targets B cells.
Side effects and open questions
Twenty-four of the 26 patients developed mild to moderate cytokine release syndrome, an immune reaction. Three experienced mild neurological side effects. In both groups, these side effects resolved without lasting problems. Five patients developed grade 3 or 4 neutropenia—severely low counts of neutrophils, a type of white blood cell that helps fight infection. One patient temporarily needed a breathing machine because of swelling in the neck.
Researchers compared each patient’s results before and after the infusion. Without a separate comparison group, it is difficult to determine how much of the improvement came from the treatment. It's clear: further research is needed to clarify how long the benefits last, how safe the treatment is over time, and whether it helps people with other forms of SPS.
The findings could also guide research into other autoimmune disorders of the nervous system with few treatment options. “Until we have long-term data and a controlled study, it’s too early to say whether this is a breakthrough,” Professor Shelly concludes.


